Wells Fargo’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-24,987
| Closed | -$5K | – | 6894 |
|
|
2018
Q1 | $5K | Buy |
24,987
+4,858
| +24% | +$4.48K | ﹤0.01% | 6085 |
|
|
2017
Q4 | $26K | Sell |
20,129
-11,050
| -35% | -$18K | ﹤0.01% | 5734 |
|
|
2017
Q3 | $66K | Sell |
31,179
-14,459
| -32% | -$35.3K | ﹤0.01% | 5388 |
|
|
2017
Q2 | $132K | Buy |
45,638
+1,100
| +2% | +$3.3K | ﹤0.01% | 5036 |
|
|
2017
Q1 | $153K | Buy |
44,538
+20,988
| +89% | +$82.8K | ﹤0.01% | 4978 |
|
|
2016
Q4 | $41K | Buy |
23,550
+8,620
| +58% | +$20.3K | ﹤0.01% | 5441 |
|
|
2016
Q3 | $49K | Buy |
14,930
+8,945
| +149% | +$33.8K | ﹤0.01% | 5303 |
|
|
2016
Q2 | $26K | Sell |
5,985
-4,089
| -41% | -$18.5K | ﹤0.01% | 5437 |
|
|
2016
Q1 | $57K | Buy |
10,074
+227
| +2% | +$2.95K | ﹤0.01% | 5180 |
|
|
2015
Q4 | $170K | Sell |
9,847
-31,480
| -76% | -$751K | ﹤0.01% | 4559 |
|
|
2015
Q3 | $872K | Sell |
41,327
-33
| -0.1% | -$1.13K | ﹤0.01% | 3585 |
|
|
2015
Q2 | $2.05M | Buy |
41,360
+38,056
| +1,152% | +$2.28M | ﹤0.01% | 3086 |
|
|
2015
Q1 | $258K | Sell |
3,304
-21,785
| -87% | -$1.35M | ﹤0.01% | 4298 |
|
|
2014
Q4 | $1.52M | Buy |
25,089
+18,531
| +283% | +$931K | ﹤0.01% | 3213 |
|
|
2014
Q3 | $279K | Buy |
6,558
+764
| +13% | +$41K | ﹤0.01% | 4205 |
|
|
2014
Q2 | $358K | Buy |
5,794
+1,599
| +38% | +$93K | ﹤0.01% | 4092 |
|
|
2014
Q1 | $273K | Buy |
4,195
+565
| +16% | +$38.2K | ﹤0.01% | 4191 |
|
|
2013
Q4 | $205K | Sell |
3,630
-1,356
| -27% | -$76.2K | ﹤0.01% | 4238 |
|
|
2013
Q3 | $306K | Sell |
4,986
-30,117
| -86% | -$2.04M | ﹤0.01% | 3994 |
|
|
2013
Q2 | $2.05M | Buy |
+35,103
| New | +$2.16M | ﹤0.01% | 2798 |
|
Other funds holding OREX
Wells Fargo's OREX Position: Q2 2018 in Review
Wells Fargo sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 24,987 shares — an estimated $5K sold.
Wells Fargo first reported a position in OREX in Q2 2013 and held it in 20 quarters. The position peaked at $2.05M in Q2 2013. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.
- Wells Fargo reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
- Wells Fargo sold 24,987 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $5K.
- Wells Fargo first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 20 quarters.
- Wells Fargo's Orexigen Therapeutics, Inc. position peaked at $2.05M in Q2 2013.
- 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.
Based on Wells Fargo's 13F filing for Q2 2018, filed 1 Aug 2018.